Manon J. Pepels

670 citations

35 papers · 400 indexed · h-index 11

Co-authors: Vivianne C. G. Tjan‐Heijnen George F. Borm Peter Bult Maaike de Boer P. J. van Diest Marian B. E. Menke‐Pluymers Rob B. van der Luijt R. J. L. F. Loffeld
Topics: Breast Cancer Treatment Studies (26 papers)Advanced Breast Cancer Therapies (10 papers)Cancer Treatment and Pharmacology (9 papers)
Cited by: Cancer Research Pathology and Forensic Medicine Oncology
Journals: Journal of Clinical Oncology PLoS ONE Cancer Research
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Manon J. Pepels

34 papers receiving 394 citations

Peers

Countries citing papers authored by Manon J. Pepels

Since Specialization

Citations

This map shows the geographic impact of Manon J. Pepels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manon J. Pepels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manon J. Pepels more than expected).

Fields of papers citing papers by Manon J. Pepels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manon J. Pepels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manon J. Pepels. The network helps show where Manon J. Pepels may publish in the future.

Co-authorship network of co-authors of Manon J. Pepels

This figure shows the co-authorship network connecting the top 25 collaborators of Manon J. Pepels. A scholar is included among the top collaborators of Manon J. Pepels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manon J. Pepels. Manon J. Pepels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study 2025 ·The Breast ·(unknown),(unknown),Sandra M. E. Geurts,Jolien Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. Wouter Dercksen,Franchette van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen,Maaike de Boer	0
2	202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study 2024 ·ESMO Open ·(unknown),Sandra M. E. Geurts,J. Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. W. Dercksen,F. Van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),V.C.G. Tjan-Heijnen,Maaike de Boer	1
3	Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry 2024 ·Breast Cancer Research and Treatment ·Sandra M. E. Geurts,(unknown),(unknown),(unknown),Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,M. Wouter Dercksen,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Agnès J. van de Wouw,(unknown),(unknown),Thiemo J. A. van Nijnatten,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	3
4	The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown),(unknown),Ingeborg J. H. Vriens,(unknown),Sanne Engelen,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,(unknown),Sandra M. E. Geurts,Vivianne C. G. Tjan‐Heijnen	4
5	Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry 2023 ·The Lancet Regional Health - Europe ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen	15
6	Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry 2023 ·Clinical Breast Cancer ·(unknown),Sandra M. E. Geurts,(unknown),(unknown),Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,(unknown),M. Wouter Dercksen,Manon J. Pepels,Natascha A. J. B. Peters,(unknown),Agnès J. van de Wouw,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen	1
7	Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown),Sandra M. E. Geurts,(unknown),Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,M. Wouter Dercksen,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,(unknown),Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	7
8	233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry 2023 ·ESMO Open ·Sandra M. E. Geurts,(unknown),(unknown),Frans Erdkamp,Joan B. Heijns,J. Tol,Birgit E. P. J. Vriens,(unknown),(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,A. van de Wouw,(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
9	The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry 2021 ·International Journal of Cancer ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	10
10	Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands 2021 ·Value in Health ·P. Schneider,Bram Ramaekers,Xavier Pouwels,Sandra M. E. Geurts,(unknown),Maaike de Boer,Birgit E. P. J. Vriens,(unknown),(unknown),Manon J. Pepels,Vivianne C. G. Tjan‐Heijnen,Manuela Joore	6
11	248P The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry 2021 ·Annals of Oncology ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
12	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. 2019 ·The Breast ·(unknown),Sandra M. E. Geurts,(unknown),Sander Croes,Birgit E. P. J. Vriens,Franchette W.P.J. van den Berkmortel,M. Wouter Dercksen,Agnès J. van de Wouw,Manon J. Pepels,(unknown),D.J.A. Lobbezoo,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
13	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) 2019 ·Breast Cancer Research ·Stefanie de Groot,Hanno Pijl,Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Hein Putter,Marta Fiocco,Gerrit‐Jan Liefers,Jacobus J. M. van der Hoeven,J.W.R. Nortier,Judith R. Kroep	7
14	Off to a good start after a cancer diagnosis: implementation of a time out consultation in primary care before cancer treatment decision 2019 ·Journal of Cancer Survivorship ·(unknown),Niek J. de Wit,(unknown),(unknown),(unknown),(unknown),Manon J. Pepels,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Esther Jacobs,Elsken van der Wall,Charles W. Helsper	12
15	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) 2014 ·Annals of Oncology ·Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,N.A.T. Hamdy,Hein Putter,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,E. Maartense,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Martin N.J.M. Wasser,A. Elise van Leeuwen‐Stok,Gerrit‐Jan Liefers,C.J.H. van de Velde,J. W. R. Nortier,Judith R. Kroep	31
16	Is the sentinel lymph node pathology protocol in breast cancer patients associated with the risk of regional recurrence? 2013 ·European Journal of Surgical Oncology ·(unknown),Manon J. Pepels,Carla Wauters,R.F.M. Schapers,Jos W. R. Meijer,Luc J. A. Strobbe,C.L.H. van Berlo,Jean H. G. Klinkenbijl,Th. Wobbes,Adri C. Voogd,Peter Bult,Vivianne C. G. Tjan‐Heijnen	4
17	Models predicting non-sentinel node involvement also predict for regional recurrence in breast cancer patients without axillary treatment 2013 ·European Journal of Surgical Oncology ·Manon J. Pepels,(unknown),Maaike de Boer,Peter Bult,J.A.A.M. van Dijck,Marian B. E. Menke‐Pluijmers,P. J. van Diest,George F. Borm,Vivianne C. G. Tjan‐Heijnen	5
18	Relevant impact of central pathology review on nodal classification in individual breast cancer patients 2012 ·Annals of Oncology ·(unknown),Manon J. Pepels,Maaike de Boer,George F. Borm,Carolien H. M. van Deurzen,P. J. van Diest,J.A.A.M. van Dijck,Eddy Adang,J.W.R. Nortier,Emiel J. Rutgers,C. Seynaeve,Marian B. E. Menke‐Pluymers,Peter Bult,Vivianne C. G. Tjan‐Heijnen	26
19	Regional Recurrence in Breast Cancer Patients With Sentinel Node Micrometastases and Isolated Tumor Cells 2011 ·Annals of Surgery ·Manon J. Pepels,Maaike de Boer,Peter Bult,(unknown),Rob B. van der Luijt,Marian B. E. Menke‐Pluymers,P. J. van Diest,George F. Borm,Vivianne C. G. Tjan‐Heijnen	81
20	Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review 2010 ·Breast Cancer Research and Treatment ·Manon J. Pepels,(unknown),Maaike de Boer,Marjolein L. Smidt,Paul J. van Diest,George F. Borm,Vivianne C. G. Tjan‐Heijnen	55

About Manon J. Pepels

Manon J. Pepels is a scholar working on Cancer Research, Oncology and Complementary and Manual Therapy, having authored 35 papers that have together received 400 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (26 papers), Advanced Breast Cancer Therapies (10 papers) and Cancer Treatment and Pharmacology (9 papers). The work is most often cited by research in Cancer Research (230 citations), Pathology and Forensic Medicine (156 citations) and Oncology (152 citations). Manon J. Pepels has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Vivianne C. G. Tjan‐Heijnen, George F. Borm, Peter Bult, Maaike de Boer, P. J. van Diest, Marian B. E. Menke‐Pluymers, Rob B. van der Luijt, R. J. L. F. Loffeld, Marjolein L. Smidt and L.G.J.B. Engels. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact